Skip to main content

Closed

RNA: Atrium Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+14.0% / yr

Operating margin-318.7%

ROIC-23.9%

Financially safe

Stretched

Debt / equity0.01×

Interest coverage0.0×

Current ratio13.04×

Atrium Therapeutics, Inc.

RNANASDAQ Global Select·USD·Closed

Atrium Therapeutics, Inc.

RNANASDAQ·USD·Closed

$11.35

−0.96%

$11.35

−$0.11 (0.96%)

52W Range

4thpctl

Volume

0.56×avg

Mkt Cap

194.15MUSD

P/E

-4.3TTM

Div Yield

–ann

52W Range

4thpctl

Volume

0.56×avg

Market Cap

194.15MUSD

P/E Ratio

-4.3TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings